ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Reproduction
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1490839
Serum concentrations of medroxyprogesterone acetate were undetectable on OPU+5 days and had no effect on the serum progesterone level in patients undergoing the progestinprimed ovarian stimulation protocol
Provisionally accepted
Xin Chen1,2
Xu Yan1Hongyi Xu1Yueyue Hu2Shengfang Jiang2
Xiaoning Wang1Haiying Peng1Bo Feng1
Changjun Zhang1Honglu Diao1
Ying Zhang1,2*- 1Hubei University of Medicine, Shiyan, China
- 2Reproductive Medicine Center, Renmin Hospital, Hubei University of Medicine, Shiyan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate the dynamics of serum medroxyprogesterone acetate (MPA) concentrations and their influence on serum progesterone (P) levels and pregnancy outcomes in the progestin-primed ovarian stimulation (PPOS) protocol. A total of 116 patients who underwent in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment using the PPOS protocol were included. Serum MPA levels were measured on the third, fifth, and seventh days of MPA use; on the day of human chorionic gonadotropin (hCG) trigger; and two and five days after oocyte pick-up (OPU).Results: The serum MPA concentration was 2.26 ± 2.11 nmol/L on the hCG trigger day, 0.37 ± 0.40 nmol/L two days after OPU, and zero five days after OPU. There were no statistically significant differences in P levels on the hCG trigger day, total dosage of Gn, duration of Gn, number of oocytes retrieved, number of mature oocytes, fertilization rate, blastocyst progression rate, CPR, ectopic pregnancy rate, early pregnancy loss rate, or live birth rate (LBR) between the two cohorts (P > 0.05).Conclusion(s): Serum concentrations of MPA had no effect on serum P levels or pregnancy outcomes in patients undergoing the PPOS protocol.
Keywords: Progestin-primed ovarian stimulation, Medroxyprogesterone Acetate, Progesterone level, MPA concentrations, Pregnancy Outcome
Received: 03 Sep 2024; Accepted: 24 Apr 2025.
Copyright: © 2025 Chen, Yan, Xu, Hu, Jiang, Wang, Peng, Feng, Zhang, Diao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ying Zhang, Hubei University of Medicine, Shiyan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.